Pharmaceuticals
Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis
HANGZHOU, China, Aug. 9, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK01001 for the treatment of atopic dermatitis. The study was...
Race Strategic Update August 2023
SYDNEY, Aug. 9, 2023 /PRNewswire/ -- Race Oncology Limited ("Race") is pleased to provide a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene's commercial partnering and collaboration potential. Ev...
Neuragenex Expands to Open New Illinois Location, Giving More People Access to its Innovative Approach to Chronic Pain Management
CHICAGO, Aug. 8, 2023 /PRNewswire/ -- Neuragenex, a trailblazing pain management practice at the forefront of pain management solutions, is delighted to announce the opening of four new locations inIllinois. With its groundbreaking approach to chronic pain management that is drug-free and non-in...
Neuragenex Expands to Open New Utah Location, Giving More People Access to its Innovative Approach to Chronic Pain Management
SALT LAKE CITY, Aug. 8, 2023 /PRNewswire/ -- Neuragenex, a trailblazing pain management practice at the forefront of pain management solutions, is delighted to announce the opening ofBluffdale and Lehi clinic locations in Utah. With its groundbreaking approach to chronic pain management that is d...
Neuragenex Expands to Open New Georgia Locations, Giving More People Access to its Innovative Approach to Chronic Pain Management
ATLANTA, Aug. 8, 2023 /PRNewswire/ -- Neuragenex, a trailblazing pain management practice at the forefront of pain management solutions, is delighted to announce the opening of theLawrenceville clinic location in Georgia. With its groundbreaking approach to chronic pain management that is drug-fr...
Neuragenex Expands to Open New Texas Location, Giving More People Access to its Innovative Approach to Chronic Pain Management
VICTORIA and WACO, Texas, Aug. 8, 2023 /PRNewswire/ -- Neuragenex, a trailblazing pain management practice at the forefront of pain management solutions, is delighted to announce the opening of theWaco and Victoria clinic locations inTexas. With its groundbreaking approach to chronic pain managem...
Vatech Announces Distribution Through Henry Schein to Help Oral Health Professionals Enhance Access to Cutting-Edge Imaging Solutions
HWASEONG, South Korea, Aug. 8, 2023 /PRNewswire/ -- Vatech, a global leader in the dental imaging market, has announced that its products will be distributed byHenry Schein, helping to expand the availability of its cutting-edge products for dental clinics inNorth America. Vatech's portfolio o...
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updat...
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...
Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer
ROCKVILLIE, Md. and SUZHOU, China, Aug. 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
Pfizer Malaysia, Sunway Medical Centre Velocity and Sunway Multicare Pharmacy Collaborate to Raise Awareness on the Importance of Early Detection of Atrial Fibrillation
KUALA LUMPUR, Malaysia, Aug. 8, 2023 /PRNewswire/ -- Pfizer Malaysia, Sunway Medical Centre Velocity and Sunway Multicare Pharmacy, have entered a tripartite collaboration on AF360, a program highlighting the importance of early detection of Atrial Fibrillation (AF). AF is a devastating heart dis...
First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma
MELBOURNE, Australia, Aug. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase I study of the Company's investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with p...
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
* Oversubscribed transaction led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed, Pivotal Life Sciences, RA Capital Management and TCGX * $100 million financing upfront wi...
Ligandal Inc. Appoints Tushar Nuwal as Chief Operating Officer and Chief Business Officer
NEW YORK, Aug. 7, 2023 /PRNewswire/ -- Ligandal Inc., an early-stage genetic medicine biotechnology company, announces the appointment of Tushar Nuwal as Chief Operating Officer and Chief Business Officer. Mr. Nuwal brings 20 years of biopharmaceutical experience, including roles at small and lar...
6-Month Registered Clinical Trial Data on World's First Transbronchial Pulmonary Radiofrequency Ablation System for Lung Cancer Announced, Showing Significant Efficacy
HANGZHOU, China, Aug. 7, 2023 /PRNewswire/ -- During the Chinese Medical Association 11th National Academic Conference on Respiratory Endoscopy and Interventional Pulmonology on August 5, Broncus (2216.HK) announced postoperative 6-month data of a registered clinical trial on RF II, the world's ...
Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer
BEIJING, SHANGHAI and BOSTON, Aug. 7, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that Jacobio's in-house KRAS G12C inhibitor glecirasib was granted breakthrough therapy designation (BTD) by the Center for Drug ...
DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors
SHANGHAI, Aug. 7, 2023 /PRNewswire/ -- Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate ("ADC") therapeutics to treat patients with cancer and autoimmune diseases, today announ...
BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody
WUXI, China, Aug. 7, 2023 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC3448 (CD3/EGFR Bispecific antibody, BsAb). As a result, BioCity Biopharma will...
The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC
HONG KONG, Aug. 7, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that eClinical Medicine(IF:15.1), a sub-j...
Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL
ROCKVILLE, Md. and SUZHOU, China, Aug. 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that lisaftoclax (APG-2575), a novel Bcl-2 inhibitor...
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00